528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
Saved in:
| Title: | 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant? |
|---|---|
| Authors: | Thibault, G.1 (AUTHOR), Kfoury, M.2 (AUTHOR), Lorusso, D.3 (AUTHOR), Floquet, A.4 (AUTHOR), Ventriglia, J.5 (AUTHOR), Salaun, H.6 (AUTHOR), Moubarak, M.7 (AUTHOR), Rivoirard, R.8 (AUTHOR), Polastro, L.9 (AUTHOR), Favier, L.10 (AUTHOR), You, B.11 (AUTHOR), Berton-Rigaud, D.12 (AUTHOR), De La Motte Rouge, T.13 (AUTHOR), Mansi, L.14 (AUTHOR), Abdeddaim, C.15 (AUTHOR), Prulhiere, K.16 (AUTHOR), Lancry Lecomte, L.17 (AUTHOR), Provansal Gross, M.18 (AUTHOR), Dalban, C.19 (AUTHOR), Ray-Coquard, I.L.20 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS787-S788. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.656 |
